Ocular Pain Management

Topical anesthetics: in-office only, never dispensed

Proparacaine 0.5% and tetracaine 0.5% provide rapid in-office analgesia for procedures such as tonometry, foreign body removal, corneal scraping, and examination of a painful eye. However, repeated unsupervised use is directly toxic to the corneal epithelium and corneal nerves. Anesthetic abuse can rapidly cause anesthetic keratopathy: large epithelial defects, ring infiltrates, stromal melting, neurotrophic ulceration, and permanent scarring. Because the medication masks pain while damage progresses, patients often present late with severe disease.

Topical anesthetics must never be prescribed or dispensed for home use. Outpatient pain control should rely on safer strategies: cycloplegia, surface protection, topical NSAIDs when appropriate, and systemic analgesics. If a patient requests additional anesthetic drops, it is an opportunity to re-evaluate the underlying cause and ensure the pain management plan is adequate.

Cycloplegia for ciliary spasm

In corneal abrasions, foreign bodies, traumatic iritis, and anterior uveitis, much of the deep aching pain is driven by ciliary muscle spasm. Cycloplegic agents from the cycloplegics page relax the ciliary body and iris sphincter, providing meaningful pain relief that oral analgesics alone often cannot match.

Agent selection should match the expected duration of the condition. Cyclopentolate 1% (duration ~12–24 hours) is appropriate for moderate abrasions or traumatic iritis when a next-day follow-up is planned. Homatropine 5% (duration ~1–3 days) offers longer coverage for significant uveitis or larger injuries. Atropine 1% (duration up to 1–2 weeks) is reserved for severe uveitis where sustained cycloplegia is needed to prevent posterior synechiae and manage intense spasm. Patients should be counseled about pupil dilation, light sensitivity, and near blur.

Topical NSAIDs for surface pain

Topical NSAIDs such as ketorolac (Acular) can provide meaningful analgesia for corneal surface pain by reducing prostaglandin-mediated inflammation at the site of injury. They are most useful for short-term pain after PRK, corneal abrasion, or foreign body removal. However, they should be used cautiously on non-healed epithelium, kept to the shortest effective course, and avoided in eyes with significant surface compromise (neurotrophic disease, severe dry eye, autoimmune conditions) due to the risk of delayed healing and rare corneal melting. See the NSAID page for full drug comparisons and safety details.

Bandage contact lenses for epithelial defects

For large or highly symptomatic epithelial defects, a high-Dk silicone hydrogel bandage contact lens (BCL) protects exposed corneal nerve endings from lid and blink trauma, providing rapid comfort and supporting re-epithelialization. BCLs are commonly used after PRK, for large traumatic abrasions, and in recurrent corneal erosion (RCE) management. When a BCL is placed, prophylactic topical antibiotic coverage is standard, and close follow-up (typically 24–48 hours) is essential to confirm healing and rule out infection. BCLs are contraindicated in active or suspected microbial keratitis, fungal disease, or ulcers of uncertain etiology.

Oral analgesics as adjuncts

Oral analgesics complement topical and procedural pain strategies but should not substitute for treating the underlying cause.

• Oral NSAIDs (ibuprofen, naproxen) are often first-line for inflammatory ocular pain (abrasions, scleritis, uveitis, post-operative discomfort) because they address the prostaglandin-mediated component systemically. Contraindications include GI ulcer history, significant renal disease, anticoagulation, and aspirin-exacerbated respiratory disease.
• Acetaminophen is a reasonable alternative when oral NSAIDs are contraindicated. It provides analgesia without anti-inflammatory effect, so it is less effective for conditions driven primarily by inflammation.
• Opioids are rarely indicated for routine ocular pain and should be avoided in most eye care settings. Standard approaches — cycloplegia, topical NSAIDs, BCL, and oral NSAIDs/acetaminophen — are effective for the vast majority of painful eye conditions.

Pain out of proportion: red flags and differentials

Pain that is out of proportion to clinical findings or that worsens despite appropriate treatment should trigger immediate reassessment. Key differentials include:

• Microbial keratitis: Especially if an infiltrate is new, enlarging, or not responding to empiric therapy.
• Scleritis: Deep, boring pain that may radiate to the brow, temple, or jaw, often worse at night and on eye movement. May appear as sectoral or diffuse scleral injection that does not blanch with phenylephrine. Requires systemic anti-inflammatory therapy and may signal underlying autoimmune disease.
• Acute angle-closure: Sudden onset severe pain with headache, nausea, halos, and reduced vision. Requires emergent IOP reduction and laser peripheral iridotomy.
• Endophthalmitis: Rapidly progressive pain and vision loss, especially in the post-surgical or post-injection setting. Requires urgent referral.
• Retained foreign body: Persistent foreign body sensation despite treatment may indicate embedded material or a subtarsal foreign body missed on initial exam.

Clear return precautions and short-interval follow-up are essential components of any pain management plan. Pain control should never obscure a worsening diagnosis.

Chronic and neuropathic ocular pain

Some patients develop persistent ocular pain that outlasts the original insult, often described as burning, aching, or foreign body sensation without corresponding corneal findings. This pattern — sometimes termed corneal neuralgia or neuropathic corneal pain — can follow herpetic keratitis, refractive surgery, dry eye disease, or repeated corneal injuries. Standard anti-inflammatory and surface therapies may provide incomplete relief. Management is often multimodal: aggressive lubrication, autologous serum tears, low-dose oral neuropathic agents (gabapentin, pregabalin, or low-dose tricyclics with appropriate systemic screening), and co-management with pain medicine or neurology when needed. Recognizing neuropathic pain early avoids prolonged use of topical anti-inflammatories that may not address the underlying mechanism.